Evidence map›Paper›PMID 24304495›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2014

Allospecific rejection of MHC class I-deficient bone marrow by CD8 T cells.

F Haspot, H W Li, C L Lucas, T Fehr, S Beyaz, M Sykes

Abstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. CD8Immunology and cell biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

F HaspotDepartment of Surgery, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
H W Li
C L Lucas
T Fehr
S Beyaz
M Sykes

Funding

XENOGRAFT TOLERANCE THROUGH MIXED CHIMERISMP01AI045897 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Megan Sykes · 2000 to 2026
$71.9M
XENOGENIC TOLERANCE IN MICEP01HL018646 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1985 to 2019
$37.5M
MIXED CHIMERISM AS AN APPROACH TO TRANSPLANT TOLERANCER01HL049915 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI SYKES, MEGAN · 1993 to 2010
$3.9M
Pig to human thymic xenotransplantationR01AI084903 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2010 to 2014
$2.5M
NHLBI NIH HHS P01 HL018646NHLBI NIH HHS P01 HL18646NHLBI NIH HHS R01 HL049915NHLBI NIH HHS R01 HL49915NIAID NIH HHS P01 AI045897NIAID NIH HHS R01 AI084903
6 · The paper itself

Abstract

Avoidance of long-term immunosuppression is a desired goal in organ transplantation. Mixed chimerism offers a promising approach to tolerance induction, and we have aimed to develop low-toxicity, nonimmunodepleting approaches to achieve this outcome. In a mouse model achieving fully MHC-mismatched allogeneic bone marrow engraftment with minimal conditioning (3 Gy total body irradiation followed by anti-CD154 and T cell-depleted allogeneic bone marrow cells), CD4 T cells in the recipient are required to promote tolerance of preexisting alloreactive recipient CD8 T cells and thereby permit chimerism induction. We now demonstrate that mice devoid of CD4 T cells and NK cells reject MHC Class I-deficient and Class I/Class II-deficient marrow in a CD8 T cell-dependent manner. This rejection is specific for donor alloantigens, since recipient hematopoiesis is not affected by donor marrow rejection and MHC Class I-deficient bone marrow that is syngeneic to the recipient is not rejected. Recipient CD8 T cells are activated and develop cytotoxicity against MHC Class I-deficient donor cells in association with rejection. These data implicate a novel CD8 T cell-dependent bone marrow rejection pathway, wherein recipient CD8 T cells indirectly activated by donor alloantigens promote direct killing, in a T cell receptor-independent manner, of Class I-deficient donor cells.

Indexed as

Bone Marrow TransplantationTransplantation, HomologousAnimalsBone MarrowCD8-Positive T-LymphocytesH-2 AntigensImmune ToleranceIsoantigensMiceTransplantation ChimeraTransplantation ConditioningTransplantation, IsogeneicH-2 AntigensIsoantigensBone marrow transplantationCD8 T cellsindirect alloreactivitytolerance

Identifiers

PMID24304495
PMCPMC4045013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.